4//SEC Filing
PRASAD SUYASH 4
Accession 0001209191-20-052463
CIK 0001806310other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 4:39 PM ET
Size
7.0 KB
Accession
0001209191-20-052463
Insider Transaction Report
Form 4
PRASAD SUYASH
CMO and Head of R&D
Transactions
- Conversion
Common Stock
2020-09-28+3,844→ 672,589 total - Conversion
Series B Preferred Stock
2020-09-28−3,529→ 0 total→ Common Stock (3,844 underlying)
Footnotes (1)
- [F1]Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001679129
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 4:39 PM ET
- Size
- 7.0 KB